Prescribers and drug withdrawals

Australian Prescriber

Volumn 28, Issue 3, 2005, Pages 54-55

  Shenfield, Gillian ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

COX inhibitors; Drug industry; Drug regulation

Indexed keywords

CELECOXIB; CERIVASTATIN; MIBEFRADIL; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB;

CLINICAL PRACTICE; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; EDITORIAL; PHYSICIAN ATTITUDE; PRESCRIPTION;

EID: 20444426245     PISSN: 03128008     EISSN: None     Source Type: Journal    
DOI: 10.18773/austprescr.2005.043     Document Type: Editorial

References (6)

1. Summerskill W. Evidence-based practice and the individual. Lancet 2005;365:13-14.
2. Vioxx: an unequal partnership between safety and efficacy. Lancet 2004;364:1287-8.
3. Peterson WL, Cryer B. COX-1-sparing NSAIDs - is the enthusiasm justified? JAMA 1999;282:1961-3.
4. Kerr SJ, Mant A, Horn FE, McGeechan K, Sayer GP. Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners. Med J Aust 2003;179:403-7.
5. Day R. How to make the most of a visit from a pharmaceutical company representative. Aust Prescr 2000;23:97-9.
6. NPS News. Mind the gaps: how much do we really know about new drugs? NPS News 2004;37. http://www.nps.org.au/healthpro Go to Quick Links, Newsletter Index, No. 37.